Seeking Alpha

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral ...

– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo ...
Nasdaq

Assembly Biosciences Reports Positive Phase 1b Results for ABI-4334 in Chronic HBV Infection, Supporting Collaboration with Gilead Sciences

Assembly Biosciences reported positive Phase 1b results for ABI-4334 in chronic HBV, showing strong antiviral activity and favorable safety. Assembly Biosciences, Inc. has announced positive results ...
Seeking Alpha

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing ...

--Assembly Biosciences, Inc., a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced positive interim results from two Phase 1 b studies of its ...